SMS Pharma Q3 FY26 Results: Net Profit ₹233.38 Cr, Investment in Subsidiary
SMS Pharmaceuticals Limited reported Q3 FY26 un-audited results. Standalone net profit was ₹23.34 crore and consolidated net profit was ₹23.19 crore for the quarter ended December 31, 2025. The company also approved an investment of up to ₹7 crore in its subsidiary, SMS Peptides Private Limited.
The financial results show a profit for the quarter, and the investment in the subsidiary is a significant strategic move, which could impact future performance.
The company reported positive financial results and approved further investment in its subsidiary, indicating growth and strategic expansion.
SMS Pharmaceuticals Limited announced its standalone and consolidated un-audited financial results for the third quarter and nine months ended December 31, 2025. The company's Board of Directors, in a meeting held on February 7, 2026, approved these results.
For the third quarter ended December 31, 2025, the company reported a standalone net profit of ₹2,333.80 lakhs (₹23.34 crore). The consolidated net profit for the same period stood at ₹2,318.95 lakhs (₹23.19 crore).
Additionally, the Board approved a further investment of up to ₹7 crore in its subsidiary, M/s. SMS Peptides Private Limited, through the subscription of equity share capital. This investment will be executed in one or more tranches.
The meeting commenced at 10:15 a.m. and concluded at approximately 01:45 p.m.
What to do with a filing like this
SMS Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by SMS Pharmaceuticals Limited. Read the original for the full detail.